Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International Inc    BAX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2012 | 03:34pm CEST
    By Saabira Chaudhuri 
 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAXTER INTERNATIONAL INC
04/20 BAXTER INTERNATIONAL : Introduces Comprehensive Guide for Building a Smart Infus..
04/19 BAXTER INTERNATIONAL : to Present at the UBS Global Healthcare Conference
04/19 Goldberg Law PC Announces an Investigation of Baxter International Inc.
04/19 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Baxter Internat..
04/18 BAXTER INTERNATIONAL : to Present at the Bank of America Merrill Lynch Healthcar..
04/18 BAXTER INTERNATIONAL : Shares of IV saline maker Baxter dip after employee gets ..
04/18 Lundin Law PC Announces an Investigation of Baxter International Inc. and Adv..
04/17 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Baxter Inter..
04/17 BAXTER INTERNATIONAL : BAX) Negative on Subpoena
04/14 BAXTER INTERNATIONAL INC. (NYSE : BAX) Files An 8-K Departure of Directors or Ce..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
04/19DJCardinal Swoops In, Strikes Deal -- WSJ
04/18DJCARDINAL HEALTH : $6.1 Billion Deal for Some Medtronic Operations Raises Debt Co..
04/18DJCARDINAL HEALTH : $6.1 Billion Deal for Some Medtronic Operations Raises Debt Co..
03/31 Investors bet on a quiet tech revolution in Europe
03/30 FTSE ends little changed, support from mining stocks
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
04/19 Pfizer subpoenaed in Fed's IV saline probe
04/14 Baxter faces DoJ criminal investigation into IV saline sales
04/10 Top 10 Healthcare Stocks For Dividend Growth And Income
04/06 Early-stage data support efficacy of Spark's hemophilia B candidate SPK-9001
04/03 Thanks For The 8% Raise, Dividend Growth 50!
Advertisement
Financials ($)
Sales 2017 10 193 M
EBIT 2017 1 539 M
Net income 2017 1 069 M
Finance 2017 107 M
Yield 2017 1,07%
P/E ratio 2017 29,65
P/E ratio 2018 24,63
EV / Sales 2017 2,80x
EV / Sales 2018 2,60x
Capitalization 28 659 M
More Financials
Chart BAXTER INTERNATIONAL INC
Duration : Period :
Baxter International Inc Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Full-screen chart
Technical analysis trends BAXTER INTERNATIO...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Average target price 53,6 $
Spread / Average Target 1,4%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
José E. Almeida Chairman, President & Chief Executive Officer
Scott Pleau Vice President-Operations
James K. Saccaro Chief Financial Officer & Vice President
Paul E. Martin Chief Information Officer & Vice President
Marcus Schabacker Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAXTER INTERNATIONAL I..19.26%28 659
MEDTRONIC PLC12.99%110 168
ZIMMER BIOMET HOLDINGS..17.43%24 386
HOYA CORPORATION4.33%18 336
C R BARD INC12.65%18 300
DENTSPLY SIRONA INC8.31%14 394
More Results